Status:
RECRUITING
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
Lead Sponsor:
Barts & The London NHS Trust
Collaborating Sponsors:
AtriCure, Inc.
Conditions:
Persistent Atrial Fibrillation
Atrial Fibrillation, Persistent
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persist...
Detailed Description
Atrial Fibrillation is the commonest arrhythmia and is a major cause of morbidity and mortality, often causative in ischaemic strokes and compounded by heart failure. Treatment options are limited for...
Eligibility Criteria
Inclusion
- Age \> 18 years; \< 80 years
- Persistent AF \> 1-year duration
- Left atrium size \< 6cm
- Pts should be able to provide written informed consent.
Exclusion
- Subjects currently enrolled in another investigational study except in case of observational registry with no associated treatments.
- Subject has a reversible cause of AF or transient AF
- Subject is absent of LAA or if the LAA is previously surgically ligated
- Subject has had previous cardiac surgery or abdominal surgery.
- Subject has contraindication to anticoagulation.
- Patients with hypertrophic cardiomyopathy.
- Patients with significant valve disease.
- Subject has had previous catheter or surgical ablation
Key Trial Info
Start Date :
August 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06165510
Start Date
August 2 2024
End Date
October 1 2026
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Bartholomew's Hospital
London, United Kingdom, EC1A 4AS